Short answer: To launch a GLP-1 digital clinic, you build the brand, intake and patient experience, while licensed providers evaluate each patient, screen against FDA labeling and decide whether a GLP-1 medication is appropriate. You also need brand-name pharmacy pathways, a careful approach to compounded options now that FDA has declared the national shortages resolved, HIPAA safeguards and marketing that never promises weight loss.
If you want to launch a GLP-1 digital clinic, you are stepping into the most closely watched category in telehealth. Regulators, ad platforms, payment processors and pharmacy boards are all paying attention, and the rules for compounded semaglutide and tirzepatide have changed significantly since the shortage years. The founders who build durable brands here are the ones who treat compliance as the foundation, not an afterthought.
This category is familiar territory for us. WellieMD’s founder, Jessica Lynne White, BS, MSPT, spent 27 years as a licensed physical therapist, and her own brands, including KIN Meds and PauseRx, run on WellieMD. What follows is the founder-level playbook: where FDA stands today, how brand-name and compounded pathways differ, what screening looks like, and the business steps to launch responsibly.
Where compounded GLP-1s stand with FDA today
During the national shortages of semaglutide and tirzepatide injection products, federal law gave compounders more room to prepare these drugs. Once FDA determined the shortages were resolved, that room narrowed. Here is the timeline, drawn from FDA’s own statements and the Federal Register.
| Date | FDA action | What it means for a founder |
|---|---|---|
| December 19, 2024 | FDA reaffirmed that the tirzepatide injection shortage is resolved | FDA’s enforcement discretion periods for compounding tirzepatide have since ended for both 503A pharmacies and 503B outsourcing facilities |
| February 21, 2025 | FDA determined the semaglutide injection shortage is resolved | FDA stated its enforcement discretion ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities |
| May 1, 2026 | FDA published a Federal Register notice proposing not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list | FDA said it found no clinical need for outsourcing facilities to compound these drugs from bulk substances absent a shortage. Comments were due June 29, 2026. Confirm the final status with counsel. |
| June 15, 2026 | FDA published reminders for telehealth companies that promote compounded drugs | Your website, ads and emails are squarely in scope |
What “essentially a copy” means
Federal law restricts compounders from making drugs that are essentially copies of commercially available FDA-approved products. FDA’s GLP-1 statement explains that it generally considers a compounded drug a copy when it has the same active ingredient as the commercially available product, in the same, similar or an easily substitutable strength, and the same route of administration. A limited exception exists when a prescriber determines and documents that a change produces a significant difference for an individual patient. FDA has also addressed combination products, such as semaglutide with vitamin B12, and described when those are still treated as copies.
For a founder, the practical point is this: you cannot build a business model on routine compounded copies of an approved GLP-1. Any compounded prescription must rest on an individual clinical determination by a licensed provider, documented in the chart, and filled by a licensed pharmacy that can explain its legal basis for compounding. How those rules apply to your specific formulary is a question for a healthcare attorney and your pharmacy partners, and the rules continue to evolve.
503A pharmacies and 503B outsourcing facilities
A 503A pharmacy compounds from patient-specific prescriptions. A 503B outsourcing facility registers with FDA, follows current good manufacturing practice requirements and may compound from bulk substances only in limited circumstances, such as when a substance is on the 503B bulks list or a drug is in shortage. In both cases, compounded drugs are not FDA-approved. FDA states that it does not review compounded drugs for safety, effectiveness or quality before they are marketed.
FDA has also raised concerns about compounded semaglutide made with salt forms, such as semaglutide sodium or semaglutide acetate, which differ from the active ingredient in approved products. It has reported dosing errors with compounded GLP-1 products and adverse event reports tied to them. These are exactly the details a pharmacy partner should be able to answer clearly before you list any compounded product.
Brand-name pathways
Brand-name GLP-1 medications are FDA-approved products dispensed through licensed pharmacies. For many founders, a brand-name pathway is the cleanest foundation for a GLP-1 program because the product, labeling and dosing are defined by FDA approval. Your platform should support e-prescribing to appropriate pharmacies, prior authorization workflows where relevant, and clear communication with patients about pricing, availability and refills.
If your clinic offers both brand-name and compounded options, keep them clearly separated in your copy. Never describe a compounded product as a generic, an equivalent or the same as an approved brand. FDA’s June 2026 reminders specifically warn against those claims.
Screening and contraindications from the labeling
FDA labeling is the backbone of GLP-1 screening. Your intake should be designed so a licensed provider can see every factor the labeling calls out. The details below come from the current Wegovy prescribing information, and Zepbound labeling carries a comparable boxed warning and contraindications.
Boxed warning: thyroid C-cell tumors
The Wegovy label carries a boxed warning explaining that semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures, and that it is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Providers are directed to counsel patients about the potential risk and about symptoms of thyroid tumors.
Contraindications
- Personal or family history of MTC. Your intake must ask about this directly.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Also a contraindication in the labeling.
- Known hypersensitivity to semaglutide or any of the product’s excipients.
Warnings and precautions worth surfacing at intake
The Wegovy label lists warnings including acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin or an insulin secretagogue, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions (the label says it is not recommended in patients with severe gastroparesis), hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation. Intake questions about past pancreatitis, gallbladder disease, diabetes medications, kidney issues, gastroparesis and upcoming procedures help the provider make an informed decision.
Pregnancy and contraception
The Wegovy label states it may cause fetal harm, directs discontinuation when pregnancy is recognized for patients using it for weight reduction, and advises stopping at least 2 months before a planned pregnancy because of semaglutide’s long half-life. Zepbound labeling advises that it may reduce the efficacy of oral hormonal contraceptives and describes switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose escalation. Your intake and education should cover pregnancy, plans for pregnancy, breastfeeding and contraception.
Protocol screening beyond the label
Many clinical protocols also screen for factors that are not labeled contraindications but still matter, such as a history of eating disorders, age, prior bariatric surgery and certain medications. Those protocols belong to your licensed providers. The platform’s job is to collect the information clearly. The provider’s job is to decide.
Provider evaluation and follow-up
Every GLP-1 prescription should begin with an individualized evaluation by a provider who is licensed or legally permitted to practice in the patient’s state. That evaluation reviews the intake, health history, current medications, contraindications and, when the provider calls for them, labs. Some patients will not be candidates, and the provider may recommend a different path entirely.
Follow-up is just as important. Dose changes, side effects, refills and questions about procedures or pregnancy all need a clear route back to the provider. A GLP-1 program is an ongoing relationship, which is why the workflow for check-ins and refills deserves as much attention as the first intake.
Marketing a GLP-1 brand without crossing the line
GLP-1 marketing is where most compliance problems start. FDA’s reminders to telehealth companies and the warning letters it has issued describe the claims to avoid. Here are the guardrails we follow:
- No weight-loss promises. Talk about evaluation: “See if a GLP-1 medication may be right for you.” Never promise pounds, timelines or results.
- No before and after photos. They imply typical outcomes that no one can promise an individual patient.
- Never call compounded products FDA-approved. Say clearly that compounded medications are not FDA-approved.
- No sameness claims. Do not call a compounded product a generic, an equivalent or the same as a brand-name drug.
- Be accurate about who compounds. FDA warns against branding that implies the telehealth company is the compounder.
- No “FDA-approved pharmacy” language. FDA does not approve or license pharmacies or outsourcing facilities.
- Plan for LegitScript. Major ad platforms and card networks recognize LegitScript Healthcare Certification for prescription drug advertisers.
How to launch a GLP-1 digital clinic: step by step
- Get legal guidance first. Work with a healthcare attorney on entity structure, corporate practice of medicine rules and your formulary. Our guide on how to start a telehealth business without being a doctor covers the ownership basics.
- Decide your pathways. Choose brand-name options, and decide whether any compounded option fits the current legal framework after counsel reviews it.
- Secure licensed provider coverage. Confirm which states you can serve and that providers are comfortable with GLP-1 screening, dosing and follow-up.
- Vet pharmacy partners. Ask each pharmacy about licensure, the legal basis for anything compounded, active ingredient sourcing, shipping and cold chain.
- Build a label-driven intake. Capture MTC and MEN 2 history, pancreatitis, gallbladder disease, diabetes medications, pregnancy plans, contraception and upcoming procedures.
- Set up labs, refills and follow-up. Make it easy for providers to order labs and for patients to report side effects.
- Budget realistically. See How Much Does It Cost to Start a Telehealth Business? for the categories to plan for.
- Start merchant processing and LegitScript early. Both take time and cannot be rushed.
- Review every claim before it goes live. Check your site, ads and emails against FDA’s reminders and FTC substantiation expectations.
- Test the full patient journey, then launch. Run test orders from intake to delivery before real patients arrive.
How WellieMD helps
WellieMD is a white-label telehealth platform, also called a digital clinic platform, that connects your GLP-1 brand to licensed providers, licensed 503A compounding pharmacies and brand-name pharmacy pathways. It supports branded intake, licensed provider review, e-prescribing, subscriptions, refills and lab workflows in one place. All clinical decisions stay with licensed providers, and every formulary choice should be confirmed with your own counsel.
Visit the white-label telehealth platform page for the full platform view. If you want a done-for-you team to build your brand and website, GrowPro has launched 80+ telehealth brands. We build it with you.
Frequently asked questions
Can a telehealth clinic still offer compounded semaglutide or tirzepatide?
FDA has declared both national shortages resolved, and its enforcement discretion periods have ended. Compounding copies of approved products is now restricted, with a narrow exception for a documented, patient-specific significant difference. Whether any compounded option fits your clinic is a question for a healthcare attorney and your pharmacy partners.
Are compounded GLP-1 medications FDA-approved?
No. FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are marketed. Your marketing must never suggest otherwise or describe a compounded product as a generic or equivalent of a brand-name drug.
Who should not take a GLP-1 medication?
The Wegovy label lists contraindications for people with a personal or family history of medullary thyroid carcinoma, people with MEN 2, and people with known hypersensitivity to the product. Pregnancy and several warnings also require attention. A licensed provider reviews these and other factors during evaluation.
Can I show before and after photos or promise results?
We strongly advise against it. Before and after images and weight-loss promises imply outcomes no one can promise an individual patient, and they draw scrutiny from regulators and ad platforms. Focus your marketing on education and on the evaluation process.
Do I need to be a doctor to start a GLP-1 clinic?
No. Many founders are operators or marketers. Licensed providers handle evaluation and prescribing, while you run the brand and business. How ownership is structured depends on your state, so talk to a healthcare attorney before you launch.
Your next step toward a GLP-1 digital clinic
When you launch a GLP-1 digital clinic on a foundation of licensed providers, label-driven screening, clear brand-name and compounded pathways and honest marketing, you build a brand that can stand up to scrutiny. The rules in this category keep moving, so build with counsel at your side. If you are ready to map out your GLP-1 brand, book a demo with WellieMD and we will walk through it together.
This guide is general information, not legal or medical advice. Prescription products require evaluation by a licensed provider. Compounded medications are not FDA-approved.
Sources
- U.S. Food and Drug Administration: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
- U.S. Food and Drug Administration: FDA to telehealth companies, what to know when promoting compounded drugs
- U.S. Food and Drug Administration: FDA’s concerns with unapproved GLP-1 drugs used for weight loss
- Wegovy (semaglutide) Prescribing Information, FDA label
- Zepbound (tirzepatide) Prescribing Information, FDA label
- U.S. Food and Drug Administration: Human drug compounding laws